BOTOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BOTOX (BOTOX).
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion.
| Metabolism | Metabolized via proteolytic degradation; no cytochrome P450 involvement. |
| Excretion | Primarily hepatic metabolism with biliary excretion of metabolites; renal excretion of intact toxin is negligible (<1%). Fecal elimination of metabolites accounts for >99% of clearance. |
| Half-life | Terminal elimination half-life is approximately 10-12 hours for the toxin complex in plasma; however, neuromuscular blocking effect persists for 3-6 months due to irreversible inhibition of SNARE proteins and slow nerve terminal regeneration. |
| Protein binding | Approximately 95-100% bound to plasma proteins (primarily albumin and alpha-2-macroglobulin). |
| Volume of Distribution | Approximately 0.1-0.2 L/kg, indicating limited distribution primarily to extracellular fluid and target neuromuscular junctions. |
| Bioavailability | Intramuscular: 100% (local administration); not administered orally or intravenously. Systemic bioavailability is negligible due to local metabolism and dilution. |
| Onset of Action | Intramuscular: 24-72 hours for noticeable reduction in muscle activity; peak effect at 1-2 weeks. Intradermal: 2-7 days for cosmetic effect. |
| Duration of Action | 3-6 months for therapeutic effect (e.g., dystonia, spasticity); 3-4 months for cosmetic effect. Duration depends on dose, muscle mass, and rate of nerve sprouting. |
Intramuscular injection: 20-200 units per treatment session, repeated every 3-6 months as needed. Maximum total dose: 400 units per 3 months.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment recommended for renal impairment. However, use caution in severe renal impairment due to potential increased systemic exposure. |
| Liver impairment | No specific dose adjustment guidelines available. Use with caution in severe hepatic impairment. |
| Pediatric use | Dosing based on indication: For lower limb spasticity (age ≥2 years): 4 units/kg per injection site, not to exceed 8 units/kg total per treatment or 300 units. For upper limb spasticity (age ≥2 years): 3 units/kg per injection site, not to exceed 6 units/kg total per treatment or 200 units. |
| Geriatric use | No specific dose adjustment; however, elderly patients may have reduced muscle mass; consider starting at the low end of the dosing range and titrate based on response and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BOTOX (BOTOX).
| Breastfeeding | Unknown if excreted in human milk. Molecular weight (~150 kDa) suggests minimal excretion. M/P ratio not available. Use caution in nursing mothers; risk of infant botulism theoretical. Discontinue nursing or drug based on importance to mother. |
| Teratogenic Risk | FDA Pregnancy Category C. In animal studies, decreased fetal body weight, delayed ossification, and maternal toxicity observed at doses similar to human exposure. No well-controlled human studies. Risk cannot be ruled out. During first trimester: theoretical risk of malformations due to systemic spread. Second and third trimesters: risk of fetal abnormalities low due to large molecular size limiting placental transfer. However, uterine muscle weakness and preterm labor reported with injections for cervical dystonia. Use only if benefit justifies risk. |
■ FDA Black Box Warning
Distant spread of toxin effect: Cases of spread of toxin effect beyond the injection site have been reported, causing symptoms consistent with botulinum toxin effects, including dysphagia, respiratory compromise, and death. Risk is highest in children with cerebral palsy treated for spasticity.
| Serious Effects |
["Hypersensitivity to botulinum toxin or any component of the formulation","Infection at the injection site(s)","Intended intramuscular injection in patients with bleeding disorders or anticoagulation (relative)"]
| Precautions | ["Risk of distant spread of toxin effect (see black box warning)","Dysphagia and respiratory compromise","Caution in patients with neuromuscular disorders (e.g., myasthenia gravis, ALS)","Risk of urinary retention in urologic indications","Possible anaphylactic reactions","Do not exceed recommended doses and frequency","Concomitant use with aminoglycosides or other agents interfering with neuromuscular transmission may potentiate effects"] |
| Food/Dietary | No specific food interactions reported. However, avoid alcohol for 24 hours to minimize bruising risk. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of systemic botulism (dysphagia, dysphonia, respiratory compromise). Fetal monitoring: assess fetal movements and uterine activity, especially with cervical injections. Serial ultrasounds for fetal growth restriction if systemic effects suspected. |
| Fertility Effects | Reproductive studies in animals: impaired fertility in male and female rats at high doses. In humans, no direct evidence of fertility impairment; however, potential for reduced ovulation if administered for chronic migraine (associated with hormonal changes). Use in reproductive-age women: consider contraceptive counseling. |
| Clinical Pearls | For cosmetic use, reconstitute with preservative-free 0.9% NaCl; avoid agitation to prevent denaturation. Administer within 24 hours of reconstitution. Use 1-inch needle for large muscles; 0.5-inch for facial muscles. Apply ice before injection to reduce bruising. Do not massage injection site to avoid diffusion. For spasticity or cervical dystonia, use EMG or ultrasound guidance. Avoid concurrent aminoglycosides or neuromuscular blockers to potentiate weakness. Injections near the orbit can cause ptosis; use brow compression to limit spread. Treat blepharospasm with a total of 12.5–20 U per side. For axillary hyperhidrosis, use 50 U per axilla. Effects peak at 1–2 weeks; repeat at 3-month intervals. Tachyphylaxis may occur due to neutralizing antibodies; limit total cumulative dose. |
| Patient Advice | Effects typically begin within 24–72 hours and peak at 1–2 weeks; duration is about 3–4 months. · Do not rub or massage the treated area for at least 24 hours to prevent toxin spread. · Avoid strenuous activity and alcohol for 24 hours post-injection to reduce bruising. · Report any difficulty swallowing, breathing, or speaking immediately (rare but serious). · Avoid other cosmetic procedures (e.g., facials) for 1–2 weeks. · If treating hyperhidrosis, improvement usually occurs within 1 week. · Do not use if pregnant or breastfeeding; inform doctor of all medications. · Side effects include localized pain, swelling, bruising, headache, or flu-like symptoms. · Repeat treatments are needed as effects are temporary. |